Kamada Ltd. (KMDA) Stock Score, Valuation & Financial Research
Kamada Ltd. is in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 52/100.
Quick answer for KMDA
Kamada Ltd. currently has a Wall Street Score of 52/100. The stored market price is $7.92. Its financial score is 42/100. Its valuation score is 78/100. These figures are a research snapshot, not a buy or sell recommendation.
What Kamada Ltd. does
Kamada Ltd. is a biopharmaceutical firm focused on developing, manufacturing, and distributing protein therapeutics derived from human plasma. The company operates through two core business areas: its proprietary product segment and its distribution division. Its own manufactured portfolio includes KAMRAB/KEDRAB for rabies prevention, CYTOGAM to prevent cytomegalovirus disease in transplant recipients, WINRHO SDF for immune thrombocytopenic purpura and Rhesus (Rh) isoimmunization, HEPAGAM B for hepatitis B recurrence prevention following liver transplants and for post-exposure prophylaxis, VARIZIG for post-exposure chickenpox prophylaxis, and GLASSIA for intravenous alpha-1 antitrypsin deficiency (AATD). Kamada also produces KamRho (D) for the prophylaxis of hemolytic disease of newborns and immune thrombocytopenic purpura, along with a specific antiserum for Vipera palaestinae and Echis
KMDA financial snapshot
- Wall Street Score:
- 52/100
- Current price:
- $7.92
- Market capitalization:
- $456.9M
- Revenue:
- $181.7M
- Net income:
- $20.4M
- Free cash flow:
- $16.9M
- Cash:
- $32.9M
- Total debt:
- $11.6M
- EPS:
- 0.38
- P/E ratio:
- 20.8x
- Financial score:
- 42/100
- Valuation score:
- 78/100
- Revenue score:
- 25/100
What stands out
- Reported year-over-year revenue growth is +0.0%.
- Free cash flow is $16.9M, showing positive cash generation.
- The balance sheet shows $32.9M of cash versus $11.6M of total debt, leaving more cash than debt.
What the numbers mean
Its current valuation score is 78/100, which Wall Street Score classifies as strong within the model's valuation framework.
The financial score is 42/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research KMDA
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.